Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach

PLoS One. 2013;8(1):e54182. doi: 10.1371/journal.pone.0054182. Epub 2013 Jan 23.

Abstract

The blood-brain barrier (BBB), composed of tightly organized endothelial cells, limits the availability of drugs to therapeutic targets in the central nervous system. The barrier is maintained by membrane bound efflux pumps efficiently transporting specific xenobiotics back into the blood. The efflux pump P-glycoprotein (P-gp), expressed at high levels in brain endothelial cells, has several drug substrates. Consequently, siRNA mediated silencing of the P-gp gene is one possible strategy how to improve the delivery of drugs to the brain. Herein, we investigated the potential of siRNA-chitosan nanoparticles in silencing P-gp in a BBB model. We show that the transfection of rat brain endothelial cells mediated effective knockdown of P-gp with subsequent decrease in P-gp substrate efflux. This resulted in increased cellular delivery and efficacy of the model drug doxorubicin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B / antagonists & inhibitors*
  • ATP Binding Cassette Transporter, Subfamily B / metabolism
  • Animals
  • Antibiotics, Antineoplastic / chemistry
  • Antibiotics, Antineoplastic / pharmacology
  • Biological Transport
  • Blood-Brain Barrier / cytology
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism
  • Cell Line, Transformed
  • Cell Survival / drug effects
  • Chitosan / chemistry*
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacology
  • Drug Carriers / chemistry*
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Kinetics
  • Nanoparticles / chemistry*
  • RNA, Small Interfering / genetics*
  • Rats
  • Transfection

Substances

  • ATP Binding Cassette Transporter, Subfamily B
  • Antibiotics, Antineoplastic
  • Drug Carriers
  • RNA, Small Interfering
  • Doxorubicin
  • Chitosan

Grants and funding

This work was supported by a Ph.D. grant from NTNU (Norges Teknisk-Naturvitenskapelige Universitet) (Norwegian University of Science and Technology) to JM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.